Hydroxychloroquine-induced pigmentation in rheumatic diseases : prevalence, clinical features and influencing factors
© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology..
OBJECTIVE: To describe the clinical features of Chinese patients with hydroxychloroquine (HCQ)-induced pigmentation and analyze the potential risk factors associated with HCQ-induced pigmentation.
METHODS: A cross-sectional study was conducted over a duration of 7 months, during which patients who had received HCQ treatment for >6 months were included. Data was collected through a structured questionnaire that encompassed demographic and geographic characteristics, information on HCQ and concomitant medication usage, sun exposure characteristics, and hyperpigmentation-related characteristics. Univariate and multivariate analyses were employed to calculate the statistical association between HCQ-induced pigmentation and multiple variables.
RESULTS: Out of 316 patients, 83 (26.3%) patients presented hyperpigmentation during HCQ treatment. Hyperpigmentation presented after a median duration of HCQ treatment of 12 months (interquartile range, 6.0 months-30.0 months) with a median cumulative dose of 108 g of HCQ (interquartile range, 36-288 g). The most frequently affected sites of pigmentation were the face (60.2%), lower limbs (36.1%), and hands (20.5%). There was a linear decrease in the incidence of pigmentation with increasing daily sun exposure time (p= 0.030). In the multivariate analysis, variables (cumulative HCQ dose and daily sun exposure time) were included in the final models. The results revealed an independent correlation between HCQ-induced pigmentation and daily sun exposure exceeding 1 h (OR: 0.431; 95%CI: 0.208-0.892; p= 0.023).
CONCLUSIONS: The occurrence of HCQ-induced pigmentation is not uncommon, with an incidence rate of 26.3%. Daily sun exposure time exhibited a protective effect against HCQ-induced pigmentation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - (2024) vom: 08. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yin, Zi-Jing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical features |
|---|
| Anmerkungen: |
Date Revised 08.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/rheumatology/keae217 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370779126 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370779126 | ||
| 003 | DE-627 | ||
| 005 | 20240409233126.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/keae217 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM370779126 | ||
| 035 | |a (NLM)38588566 | ||
| 035 | |a (PII)keae217 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yin, Zi-Jing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hydroxychloroquine-induced pigmentation in rheumatic diseases |b prevalence, clinical features and influencing factors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. | ||
| 520 | |a OBJECTIVE: To describe the clinical features of Chinese patients with hydroxychloroquine (HCQ)-induced pigmentation and analyze the potential risk factors associated with HCQ-induced pigmentation | ||
| 520 | |a METHODS: A cross-sectional study was conducted over a duration of 7 months, during which patients who had received HCQ treatment for >6 months were included. Data was collected through a structured questionnaire that encompassed demographic and geographic characteristics, information on HCQ and concomitant medication usage, sun exposure characteristics, and hyperpigmentation-related characteristics. Univariate and multivariate analyses were employed to calculate the statistical association between HCQ-induced pigmentation and multiple variables | ||
| 520 | |a RESULTS: Out of 316 patients, 83 (26.3%) patients presented hyperpigmentation during HCQ treatment. Hyperpigmentation presented after a median duration of HCQ treatment of 12 months (interquartile range, 6.0 months-30.0 months) with a median cumulative dose of 108 g of HCQ (interquartile range, 36-288 g). The most frequently affected sites of pigmentation were the face (60.2%), lower limbs (36.1%), and hands (20.5%). There was a linear decrease in the incidence of pigmentation with increasing daily sun exposure time (p= 0.030). In the multivariate analysis, variables (cumulative HCQ dose and daily sun exposure time) were included in the final models. The results revealed an independent correlation between HCQ-induced pigmentation and daily sun exposure exceeding 1 h (OR: 0.431; 95%CI: 0.208-0.892; p= 0.023) | ||
| 520 | |a CONCLUSIONS: The occurrence of HCQ-induced pigmentation is not uncommon, with an incidence rate of 26.3%. Daily sun exposure time exhibited a protective effect against HCQ-induced pigmentation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clinical features | |
| 650 | 4 | |a Hydroxychloroquine(HCQ) | |
| 650 | 4 | |a Influencing factors | |
| 650 | 4 | |a Pigmentation | |
| 650 | 4 | |a Prevalence | |
| 650 | 4 | |a Sun exposure | |
| 700 | 1 | |a Li, Pin |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Zuo, Dachen |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Hongtao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Fayou |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Weiqin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shuya |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Sha |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g (2024) vom: 08. Apr. |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:08 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/keae217 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 08 |c 04 | ||